Immunome, Inc. (NASDAQ:IMNM) Receives $27.17 Average Price Target from Analysts

Immunome, Inc. (NASDAQ:IMNM) has received a consensus recommendation of “Buy” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $27.17.

A number of analysts recently issued reports on IMNM shares. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research report on Monday, March 10th. Lifesci Capital started coverage on Immunome in a research report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 target price on the stock.

Insider Buying and Selling

In other news, CEO Clay B. Siegall acquired 150,000 shares of Immunome stock in a transaction dated Friday, January 31st. The stock was bought at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 669,636 shares in the company, valued at approximately $5,189,679. The trade was a 28.87 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 8.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Immunome

Institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new stake in shares of Immunome during the fourth quarter worth approximately $70,000. KLP Kapitalforvaltning AS bought a new stake in shares of Immunome during the fourth quarter worth approximately $75,000. AlphaQuest LLC boosted its holdings in shares of Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after acquiring an additional 7,867 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after acquiring an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC bought a new stake in shares of Immunome during the fourth quarter worth approximately $95,000. Institutional investors own 44.58% of the company’s stock.

Immunome Stock Performance

NASDAQ:IMNM opened at $8.77 on Tuesday. The stock’s 50-day simple moving average is $9.98 and its 200 day simple moving average is $11.78. The company has a market cap of $699.64 million, a P/E ratio of -1.08 and a beta of 1.93. Immunome has a 52-week low of $8.39 and a 52-week high of $26.70.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.